From Monsanto:

Monsanto and FMC Agricultural Solutions Expand Relationship To Benefit Corn, Cotton And Soybean Farmers

Monsanto’s Roundup Ready PLUS^® Relationship With FMC To Include Hero^® Insecticide

Tuesday January 6, 2015

Dateline:

St. Louis

EmailPDFPrintRSS

"The relationship with FMC Agricultural Solutions helps us ensure that growers have an additional tool for crop management that allows their crops to thrive"

ST. LOUIS (Jan. 2, 2015) — Monsanto Company announced today an agreement to extend the relationship with  FMC Agricultural Solutions which will benefit corn, cotton and soybean growers through Roundup Ready PLUS^® Crop Management Solutions. This agreement broadens the Roundup Ready PLUS Crop Management Solutions relationship to include Hero^® insecticide.

Monsanto’s Roundup Ready PLUS platform empowers farmers to maximize the performance of their Roundup Ready^® crops through local research-supported crop management recommendations. Monsanto’s relationship with FMC began in the fall of 2010 with the inception of Roundup Ready PLUS Weed Management Solutions. For the 2015 growing season, Roundup Ready PLUS^® Weed Management Solutions has evolved beyond weed management to become Roundup Ready PLUS Crop Management Solutions. Today, Monsanto and its partners continue to develop effective, economical and sustainable approaches to controlling tough-to-control and glyphosate-resistant weeds, as well as insects and diseases.

FMC herbicides that will continue to be endorsed under the agreement include the Authority^® brand of soybean pre-emergence residual herbicides: Authority^® Assist, Authority^® First, Authority^® Maxx, Authority^® MTZ and Authority^® XL. Information on these products, as well as incentives, is available at www.roundupreadyPLUS.com.

Hero insecticide is a powerful combination of two pyrethroid-based insecticides with complimentary activity against 45 labeled insects that other products may miss. Some of those insects include kudzu bug, aphids and mites on soybeans, as well as brown marmorated stinkbug on soybeans and some corn hybrids.

Hero insecticide is an effective tank-mix partner with fungicides, post-herbicides and foliar fertilizers and offers a broad -spectrum and increased length of control on multi-pest complexes common in corn, soybeans and cotton, as well as more than 80 labeled crops.

“The relationship with FMC Agricultural Solutions helps us ensure that growers have an additional tool for crop management that allows their crops to thrive,” said Chris Reat, Roundup Ready PLUS marketing manager at Monsanto.  “By enhancing the Roundup Ready PLUS platform with Hero^® insecticide, we are ensuring corn, soybean and cotton growers have access to an excellent product for managing insects and protecting crop yield”.

“We look forward to  extending  the Roundup Ready PLUS portfolio to include  insecticides for corn, soybean and cotton growers, and continuing this strong relationship with FMC so that we can continue to provide the highest industry standard solutions for growers’ bottom-line benefits,” Reat said.

About Monsanto Company

Monsanto is committed to bringing a broad range of solutions to help nourish our growing world. We produce seeds for fruits, vegetables and key crops – such as corn, soybeans, and cotton – that help farmers have better harvests while using water and other important resources more efficiently. We work to find sustainable solutions for soil health, help farmers use data to improve farming practices and conserve natural resources, and provide crop protection products to minimize damage from pests and disease. Through programs and partnerships, we collaborate with farmers, researchers, nonprofit organizations, universities and others to help tackle some of the world’s biggest challenges. To learn more about Monsanto, our commitments and our more than 20,000 dedicated employees, please visit: discover.monsanto.com and monsanto.com. Follow our business on Twitter® attwitter.com/MonsantoCo, on the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our News Release RSS Feed.

About FMC Corporation

FMC Corporation is a diversified chemical company serving agricultural, industrial and consumer markets globally for more than a century with innovative solutions, applications and quality products. In 2013, FMC had annual sales of approximately $3.9 billion. The company employs approximately 6,000 people throughout the world and  operates its businesses in three segments: FMC Agricultural Solutions, FMC Health and Nutrition, and FMC Minerals.  For more information, visit www.FMC.com.

-oOo-

Always read and follow label directions. Hero is a restricted use pesticide. Authority herbicides and Hero insecticide are not registered for sale or use in California but Hero EW is registered in California. FMC, Authority and Hero are trademarks of FMC Corporation. © 2014 FMC Corporation. All rights reserved.

GE & Partners Announce Winners of the First Stage of $100 M "healthymagination Cancer Challenge"

Press release:

27 March 2012

GE & Partners Announce Winners of the First Stage of $100 Million “healthymagination Cancer Challenge”

· Challenge focused on early-stage breast cancer breakthroughs that warrant discovery, incubation and acceleration through seed funding

· Winning innovations could expedite breast cancer detection, diagnosis and improve the identification of effective therapies, allowing more patients to survive

SAN FRANCISCO--27 March 2012-- GE (NYSE: GE) announced today five innovation award winners as part of the first stage of its $100 million “GE healthymagination Cancer Challenge.” More than 500 ideas from 40 countries were submitted, sparking robust conversations among more than 200 academic institutions and researchers on the Challenge’s open innovation platform.

The five innovation award winners have the potential to help doctors find cancer earlier, make more accurate diagnoses and choose the best possible treatment based on each patient’s unique cancer. The submitted ideas include ones that could help doctors better understand the molecular similarities between breast cancer and other solid tumors with a particular focus on tumors associated with triple negative cancer, a type of cancer that is less responsive to standard treatments and is typically more aggressive. GE is committed to a new approach at healthymagination that shines a spotlight on early-stage ideas to accelerate the researchers’ work and ultimately help patients sooner.

Beth Comstock, senior vice president and chief marketing officer, GE said, “We launched the Challenge as a call to action for oncology researchers, businesses, and other innovators around the world to accelerate innovation and help stop this deadly disease. It is often challenging for early stage research to grab the attention of seed investors. The Challenge has shown us that there are a remarkable number of breakthrough ideas out there that deserve promotion, investment and incubation.”

In addition to the $100,000 seed award, GE will provide support for each winner through mentorship and access to GE researchers and industry thought leaders with opportunity for expanded partnerships in the future.

“GE and Clarient focus on helping health providers understand and define the drivers of a patient’s particular cancer. The Challenge winners' work will change the future of fighting cancer,” said Carrie Eglinton-Manner, general manager of Clarient, the cancer diagnostics company acquired by GE in 2010. “In addition to the grant money, we will help mentor, develop and accelerate the growth of these winning ideas.”

The winners were selected by a panel of judges that included venture capital partners, GE executives, and several leading healthcare luminaries including former U.S. FDA Commissioner and National Cancer Institute Director, Dr. Andrew Von Eschenbach; Professor of Surgery and Director of the University of Michigan Breast Care Center, Dr. Lisa Newman; and cancer medicine specialist and Imperial College’s professor of cancer medicine, Dr. Justin Stebbing.

The five innovation Challenge award winners are:

• MyCancerGenome- Personalized Approach to Triple Negative Breast Cancer: Vanderbilt University in Nashville, Tennessee is developing MyCancerGenome, a free online cancer medicine resource and decision-making tool for physicians, patients, caregivers and researchers. It provides up-to-date information on what mutations make breast cancer grow and related treatment implications, including available genome-directed clinical trials for triple negative breast cancer.
• Creating Safer & Stronger Breast Implants with Cancer-fighting and Healing Properties: The University of Akron in Akron, Ohio is developing new materials for breast reconstruction to transform tissue expanders and implants into cancer-fighting and healing devices. Using coatings embedded with pharmaceutical agents the new device is expected to help fight infection, reduce inflammation, and possibly even target and destroy stray cancer cells.
• Identifying a Predisposition to Cancer Spread: Moffitt Cancer Center in Tampa, Florida is working to understand the genetic "modifier" genes and their role in predisposition to the spread of cancer to other parts of the body following cancer onset. This research could form the basis of diagnostic testing for genes that place a patient at disproportionate risk for cancer spread and guide aggressiveness of treatment.
• Saving Lives in Developing Countries: For developing countries such as Uganda, breast ultrasound holds promise in identifying cancers in young women with palpable lumps. Fred Hutchinson Cancer Research Center in Seattle, Washington and Uganda Cancer Institute (UCI) in Kampala are establishing a breast cancer screening program where women will receive education about breast cancer and those with symptoms will be offered clinical breast exam and breast ultrasound. Women with suspicious lumps will be referred to the UCI for tissue sampling and, if malignancy is diagnosed, treatment.
• Moving to Personalized Therapy for Triple Negative Breast Cancer: Researchers at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee have demonstrated that gene expression analysis reveals at least six distinct disease subtypes for triple negative breast cancer that likely respond differently to chemotherapy. Using this discovery, the Center is designing clinical trials with targeted therapy for select subtypes which will soon be offered to patients.

Information on the winners is available at www.healthymagination.com.

Launched in September, the Challenge is part of GE’s healthymagination commitment to accelerate cancer innovation by investing $1 billion in cancer technology research and development as well as improve care for 10 million cancer patients around the world by 2020. Additional strategic commercial partnership announcements from the Challenge will be made later in 2012. For additional details on the challenge, and to view the full terms and conditions visit healthymagination.com/challenge.

About GE

GE (NYSE: GE) works on things that matter. The best people and the best technologies taking on the toughest challenges. Finding solutions in energy, health and home, transportation and finance. Building, powering, moving and helping to cure the world. Not just imagining. Doing. GE works. For more information, visit the company's website at www.ge.com.

About GE’s healthymagination Initiative

Launched in May 2009, GE’s healthymagination initiative is focused on four critical needs: low-cost technology; healthcare IT; innovation accessible to all; and consumer-driven healthcare. GE has committed that by 2015 it will:

• Invest $3 billion in research and development to launch at least 100 innovations that will help deliver better care to more people at lower cost.
• Provide $2 billion in financing and $1 billion in technology to bring healthcare information technology to rural and underserved areas.
• Reduce the cost of procedures that use GE technologies and services by 15 percent and develop products tailored to underserved regions of the world.
• Reach 100 million more people every year with services and technologies essential for health.

More information at www.healthymagination.com.